Vaso-occlusive Crisis Clinical Trial
Official title:
A Pilot Study of the Use of Oral Ketamine for Treatment of Vaso-Occlusive Pain in Adolescents and Young Adults
The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to intravenous (IV) opioids. There is a need for improved non-opioid analgesia for patients experiencing sickle-cell crises in the hospital and prehospital setting, as children and adolescents with sickle cell disease who experience sickle-cell crises often have severe pain that is not well controlled by high dose opioids, leading to poor pain management and opioid-related side effects. The study will begin when patients are admitted to the Emergency Department of Boston Children's Hospital for treatment of a sickle-cell crisis. Oral ketamine will be administered every 8 hours for the next 48 hours. Patients will have continuous cardiorespiratory monitoring for the duration of the study, as per routine care, as well as monitoring by the hospital's Acute Pain Service at least twice daily for pain management and side effects of pain treatment. At the end of the 48-hour study duration, patients will discuss with the Pain Service and Hematology Service whether to continue oral ketamine, change to intravenous ketamine, or discontinue ketamine based on clinical indications such as level of pain and sedation while on opioids.
This is a pilot study of the feasibility of oral ketamine dosing initiated in the Emergency Department and continued for 48 hours for adolescents and young adults hospitalized with VOCs. A total of 10 patients between the ages of 12 and 24 years will receive oral ketamine 0.5 mg/kg Q8hrs for 48 hours. Pain scores using VAS and Modified Ramsey Sedation Scores will be obtained every 4 hours per routine nursing care. Vital signs (temperature, heart rate, blood pressure, and respiratory rate) will also be taken every 4 hours throughout the study duration. Side effects (such as dysphoria, dizziness, unpleasant dreams, hallucinations, headache, and nausea) will be monitored throughout the study duration. The Acute Pain Service will assess each patient at least twice daily for pain management and side effects to pain treatment. Ketamine will be discontinued for patients who experience side effects. Patients who experience continued high pain scores will have the option of having oral ketamine discontinued and IV ketamine infusion initiated. At the end of the 48 hour study period, patient, parent, Pain Service and Hematology Service will discuss whether to continue oral ketamine, change to intravenous ketamine, or discontinue ketamine based on clinical indications such as level of pain and sedation while on opioids. Patients and parents (for patients > 18 years) will be asked to complete a brief satisfaction survey at the end of the 48 hour study period. Patients who are 12-24 years of age who require admission for vaso-occlusive pain will be included. Patients who do not wish to participate or who have had side effects to previous use of intravenous ketamine for treatment of vaso-occlusive pain that would preclude using ketamine for future pain episodes will not be included in this study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03639805 -
Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis
|
N/A | |
| Withdrawn |
NCT00711698 -
Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)
|
Phase 2 | |
| Recruiting |
NCT05289700 -
Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD)
|
Phase 3 | |
| Recruiting |
NCT03412045 -
Hyperbaric Oxygen Therapy in Sickle Cell Pain
|
N/A | |
| Recruiting |
NCT05376046 -
Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
|
||
| Active, not recruiting |
NCT04935879 -
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
|
Phase 3 | |
| Terminated |
NCT01501643 -
Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease
|
N/A | |
| Terminated |
NCT01891812 -
Nitrous Oxide Analgesia Vaso-occlusive Crisis
|
Phase 2 | |
| Completed |
NCT04301336 -
Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia
|
Phase 2/Phase 3 | |
| Completed |
NCT01737814 -
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
|
Phase 3 | |
| Completed |
NCT01419977 -
Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
|
Phase 2 | |
| Completed |
NCT01119833 -
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
|
Phase 2 | |
| Not yet recruiting |
NCT06181695 -
Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric
|
Phase 3 | |
| Completed |
NCT04756375 -
Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room
|
N/A | |
| Active, not recruiting |
NCT05348915 -
A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
|
Phase 3 | |
| Enrolling by invitation |
NCT06345638 -
Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease
|
||
| Completed |
NCT03296345 -
Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis
|
Phase 2 | |
| Terminated |
NCT02179177 -
Apixaban in Patients With Sickle Cell Disease
|
Phase 3 | |
| Recruiting |
NCT03353584 -
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
|
N/A | |
| Terminated |
NCT01522196 -
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
|
Phase 2 |